Steady Performance, Deepening Second and Third Growth Curves
发布时间:2026-10-26 来源:华泰证券
Done-E-E-Jiao’s(DEEJ)3Q26 results:For 1-3Q26,revenue/attributable net profit/and recurring net profit came in at RMB4.94/1.33/1.26bn,up 4/4/9%YoY.For 3Q26,revenue/attributable net profit/recurring net profit were RMB1.79/0.47/0.44bn,up 4/2/19%YoY.Revenue and profit growth slowed on market factors,but we remain positive on the company's long-term effort to deepen and expand its ejiao category while broadening into deer antler,cistanche,and health consumer products.As the company matures,we expect sustained robust dividends and share buybacks to support investment value.Maintain OVERWEIGHT.
We expect double-digit YoY revenue growth in ejiao in 2027
We estimate ejiao series revenue grew steadily in 1-3Q26.Ejiao block and ejiao syrup drug revenue was stable YoY,ejiao cake revenue grew solidly,and ejiao powder,ejiao dates,and Huangjia Weichang products grew rapidly.We forecast single-digit YoY revenue growth for the ejiao series in 2026.With expected industry recovery and consumption rebound as well as category expansion,we forecast growth to return to double digits YoY in 2027.Drugs could grow at alow-single-digit pace,with ejiao block and ejiao syrup steady and small products like Huangjia Weichang 1619 growing at double digits.Health consumer products such as ejiao powder and ejiao cake are entering afast-growth trajectory and could become asecond growth engine over time,in our view.
Expense ratios stable,cash flow under near-term pressure
In 1-3Q26,the selling/administrative/R&D expense ratios were 33.3%/6.7%/4.0%,down 1.9pp/up 0.6pp/up 1.0pp YoY,which we view as being largely stable.2)In 3Q26,notes receivable,accounts receivable,and receivables financing combined rose by RMB630mn from end-4Q25,mainly because customers used credit lines for shipments,creating new receivables.We expect credit lines to be fully collected by year-end.Inventory fell by RMB140mn QoQ in 3Q26.3)Cash received from sales was RMB4.28bn in 1-3Q26,below revenue,mainly on higher receivables.Net operating cash flow was RMB400mn,below net profit,mainly on lower sales collections and higher marketing spend.
Dual-engine strategy:drugs plus health consumer products
We believe that during the 15th Five-Year Plan period(2026-2030),the company could evolve from an ejiao leader into aleader in broad-based tonics.1)Strengthen ejiao and core qi-blood categories,and keep scaling major products such as ejiao block,compound ejiao syrup,and Taohuaji ejiao cake.2)Build asystematic product matrix around brain,energy,and vitality needs,anchored by the Huangjia Weichang 1619 deer business and the Zhuangben cistanche business.3)Develop future growth drivers based on the three-stage beauty and anti-aging framework,supported by technical filings,clinical evidence,and mechanism validation.
Maintain OVERWEIGHT
Given pressure on drug and health product consumption,we lower our earnings forecasts.We now expect 2026/2027/2028 attributable net profit of RMB1.92/2.11/2.30bn,down 4/8/12%from previous.We apply a25x 2026E PE,in line with the Wind consensus average of 25x for comparable companies,and derive atarget price of RMB74.94,up from RMB71.83 previously,which was based on 23x 2026E PE and RMB2.00bn profit.The target price increase mainly reflects higher comparable valuations.
Risks:changes in medical insurance policy,and weaker consumption of midrange to high-end drugs than we expect.